Retina

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.

Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.

A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.

Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.

Discover how IRIS Registry real-world data turns EHR notes and images into evidence that speeds ophthalmology trials, recruitment, safety studies, and post-approval insights.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.

A glaucoma expert addressed the connection between systemic blood pressure, intraocular pressure, and glaucoma.

Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

Pivotal wet AMD, DME, and XLRP readouts; the MOGENRY BLA; and Retina Society, EURETINA, and ESCRS highlights from September.

September was one of the busiest months of the year in eye care—From ESCRS to Eyecon

Real-world VOYAGER data at EURETINA 2026 show vision and anatomic outcomes with faricimab across nAMD, DME, and RVO.

As with so many diseases, lung cancer manifests in men and women differently in type, symptoms, and prognosis.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

Could one surgery replace years of GA injections? Phase 2 ArMaDa data suggest gene therapy OCU410 slows lesion growth.

Paul Nderitu, MBChB, MPhil, MBCS, FRCOphth, PhD, gives an update at EURETINA 2026 on Global RETFound, a foundation model being built with 108 partners from more than 40 countries

4DMT's 4D-150 gene therapy enters phase 3 4SIGHT trial in DME; 2-year SPECTRA data show +10.8-letter BCVA gain in 9 patients.